Disialoganglioside GD2 is a glycolipid antigen involving in adhesion of tumor to extracellular matrix proteins. Previous studies indicate GD2 has limited expression on normal tissues such as central nervous system, peripheral nerves and skin melanocytes, but is highly expressed on surface of tumor cells. Therefore, GD2 has been recognized as a valuable therapeutic target of human cancer such as neuroblastoma and melanoma.
Anti-GD2 CAR-T Cell Therapy
Several Phase I clinical trials have been initiated to evaluate anti-GD2 CAR-T cells in patients of neuroblastoma, melanoma and GD2-positive sarcoma (NCT02107963, NCT02439788, NCT01953900 and NCT02482532). Results from completed trial indicate that GD2 specific CAR-T cells can induce complete tumor responses in patient with active neuroblastoma and extensive persistence of in patients (NCT01460901).
Creative Biolabs fully understand researches of adoptive T cell therapy targeting GD2 are time-consuming and costly. With our highly experienced technical groups and state-of-the-art facilities, Creative Biolabs can accelerate this process by providing approved in vivo tumor models and related evaluation services.
With supports from experienced technical team, Creative Biolab offers various tumor models for GD2 specific CAR-T therapy evaluation. All animal experiments are monitored under an approved Institutional Animal Care and Use Committee (IACUC) protocol.
Xenograft model of human neuroblastoma
NOD/SCID mice are subcutaneously injected (or via tail vein for systemic tumor studies) human neuroblastoma cells SH-SY5Y on right or left flank, followed by local injection of GD2 specific CAR-T cells and intraperitoneal injection of rhIL-2.
Xenograft model of human colon carcinoma
Immunocompromised mice bred in Creative Biolabs are subcutaneously inoculated with colon carcinoma cell CT26 and then receive injection of GD2 specific CAR-T cell via tail vein. Tumor sizes of mice are monitored using electronic calipers, body weight and other physiological signs are also recorded.
In vivo Assay Parameters and Techniques
Creative Biolabs offers comprehensive services to evaluate anti-GD2 CAR-T therapy. Our technical group is very experienced and strive to finish each milestone within proposed timeline.
Tumor remission monitored by tumor volume recording or bioluminescence imaging and survival curve tracking.
Viability and Bio-distribution Studies
Durability, GLP-compliant bio-distribution studies
Pilot tolerability (MTD, The route of administration, Dose regimen/response/onset)
Clinical observation (body weight, feed consumption, ophthalmologic and clinical pathology)
Cytokine storm surveillance (fever, hypertension, prolonged cytopenia)
Complete necropsy, organ weight
GLP-Compliant Preclinical Test
All our experiments are performed by well-trained and experienced technicians in a GLP-compliant and IACUC-regulated facility.
For any technical issues or products/services related questions, please leave your contacts as below, and our team will contact you at earliest convenience to let you know how we can be involved in your projects.
Nanoparticle Tiny Tech for Programming T Cells: A novel technology to increase the efficiency and value of your CAR-T therapy project.LEARN MORE
End-to-end CAR Hybrid TCR (CHyT)-T Cell Therapy Development Services: A novel solution to engineer T cell to be a promising cellular therapy with the complete TCR without HLA dependence.LEARN MORE
TRAC-CAR-T Cell Development with CRISPR/Cas9 Technology: A novel technology to build more powerful CAR-T cells.LEARN MORE